Novartis Consumer Health, Inc., a prominent player in the healthcare sector, is headquartered in the United States and operates extensively across North America and Europe. Founded in the early 2000s, the company has established itself within the consumer health industry, focusing on over-the-counter (OTC) products, dietary supplements, and personal care items. Notable for its innovative approach, Novartis Consumer Health offers a diverse range of core products, including pain relief medications and allergy treatments, which are distinguished by their efficacy and consumer trust. The company has achieved significant market presence, recognised for its commitment to quality and safety in health solutions. With a strong emphasis on research and development, Novartis Consumer Health continues to lead in providing accessible health products that enhance the well-being of consumers worldwide.
How does Novartis Consumer Health, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Novartis Consumer Health, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Novartis Consumer Health, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of GSK plc, which influences its climate commitments and initiatives. As part of its corporate family relationship with GSK plc, Novartis Consumer Health inherits various climate initiatives and targets. These include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all sourced from GSK plc. However, specific reduction targets or achievements for Novartis Consumer Health are not detailed. While no absolute emissions figures are provided, the company's alignment with GSK plc's sustainability efforts indicates a commitment to reducing carbon emissions and addressing climate change. The absence of direct emissions data suggests that Novartis Consumer Health is still in the process of establishing its own specific climate metrics and reduction strategies.
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - | 0,000,000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Novartis Consumer Health, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.